BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 - Seite 2

Abstract #

Presentation

Time (PDT)

Lead Author

Preclinical

Characterization of the correlation between BTK

degradation and tumor growth inhibition of the

BTK target protein degraders using PK/PD

modeling

2110

Monday, April 8

9 a.m. – 12:30 p.m.

Section 30

Board #1

Y. Wu

BGB-B167, a first-in-class 4-1BB/CEACAM5

bispecific antibody, exhibits potent in vitro and in

vivo anti-tumor activity and superior safety profile

in preclinical models

2371

Monday, April 8

9 a.m. – 12:30 p.m.

Section 38

Board #17

Z. Li

Translational assessment of triple combination

with tislelizumab (anti-PD-1), LBL-007 (anti-LAG-

3) and surzebiclimab (anti-TIM-3) highlights its

strong anti-tumor activity and clinical potential in

solid tumors such as HNSCC

4041

Tuesday, April 9

9 a.m. – 12:30 p.m.

Section 3

Board #17

H. Zhu

Clinical

Exploration of potential biomarkers correlated

with efficacy of ociperlimab (anti-TIGIT) plus

tislelizumab (anti-PD1) in 1L PD-L1+ non-small

cell lung cancer (NSCLC)

CT053

Monday, April 8

9 a.m. – 12:30 p.m.

Section 48

Board #3

S. Kim

A first in human, phase 1a, dose escalation study

of BGB 10188, a phosphatidylinositol 3 kinase

delta (PI3Kδ) inhibitor, + tislelizumab (anti-PD-1)